

## 2018 Current Fiscal Year Report: National Cancer Advisory Board

Report Run Date: 06/05/2019 11:04:41 AM

### 1. Department or Agency

Department of Health and Human Services

### 2. Fiscal Year

2018

### 3. Committee or Subcommittee

National Cancer Advisory Board

### 3b. GSA Committee No.

960

### 4. Is this New During Fiscal Year?

No

### 5. Current Charter

05/31/2018

### 6. Expected Renewal Date

05/31/2020

### 7. Expected Term Date

### 8a. Was Terminated During Fiscal Year?

No

### 8b. Specific Termination Authority

### 8c. Actual Term Date

### 9. Agency Recommendation for Next Fiscal Year

Continue

### 10a. Legislation Req to Terminate?

Not Applicable

### 10b. Legislation Pending?

Not Applicable

### 11. Establishment Authority Statutory (Congress Created)

### 12. Specific Establishment Authority

42 U.S.C. 284a

### 13. Effective Date

11/20/1985

### 14. Committee Type

Continuing

### 14c. Presidential?

No

### 15. Description of Committee Other Committee

### 16a. Total Number of Reports

2

### 16b. Report Date

### Report Title

07/26/2018 Report of the National Cancer Advisory Board Ad Hoc Working Group on Global Health

08/14/2018 Data Science Opportunities for the National Cancer Institute - Interim Report of the National Cancer Advisory Board Working Group on Data Science

### Number of Committee Reports Listed: 2

17a. Open 1 17b. Closed 0 17c. Partially Closed 4 Other Activities 0 17d. Total 5

### Meetings and Dates

Purpose	Start	End
Program Advisory/Second Level Peer Review	11/28/2017	- 11/29/2017
Program Advisory/Second Level Peer Review	02/13/2018	- 02/13/2018
Program Advisory	05/16/2018	- 05/16/2018
Program Advisory/Second Level Peer Review	06/25/2018	- 06/27/2018
Program Advisory/Second Level Peer Review	08/14/2018	- 08/14/2018

### Number of Committee Meetings Listed: 5

	Current FY	Next FY
18a(1). Personnel Pmts to Non-Federal Members	\$40,000.00	\$40,000.00
18a(2). Personnel Pmts to Federal Members	\$0.00	\$0.00

<b>18a(3). Personnel Pmts to Federal Staff</b>	\$82,386.00	\$87,030.00
<b>18a(4). Personnel Pmts to Non-Member Consultants</b>	\$15,200.00	\$15,200.00
<b>18b(1). Travel and Per Diem to Non-Federal Members</b>	\$26,274.00	\$26,546.00
<b>18b(2). Travel and Per Diem to Federal Members</b>	\$0.00	\$0.00
<b>18b(3). Travel and Per Diem to Federal Staff</b>	\$0.00	\$0.00
<b>18b(4). Travel and Per Diem to Non-member Consultants</b>	\$30,300.00	\$30,723.00
<b>18c. Other(rents,user charges, graphics, printing, mail, etc.)</b>	\$82,662.00	\$84,316.00
<b>18d. Total</b>	\$276,822.00	\$283,815.00
<b>19. Federal Staff Support Years (FTE)</b>	0.50	0.50

## **20a. How does the Committee accomplish its purpose?**

The National Cancer Advisory Board (NCAB), composed of both scientific and public members, provides second level peer review, makes recommendations for support of grants, contract proposals, and cooperative agreements, where direct costs per annum exceed \$50,000; advises on policy development, program implementation and evaluation; and identifies research needs of the National Cancer Institute (NCI). In FY 2018, the NCAB reviewed 15,120 NCI applications requesting \$5,142,273,938 and 7 FDA SBIR applications requesting \$1,542,025. During the year, the NCAB was presented reports on various topics related to cancer research in general. Board discussions and reports included a wide variety of topics including the President's Cancer Panel Report on Promoting Value, Affordability, and Innovation in Cancer Drug Treatment; Cervical Cancer Screening; the Common Terminology for Patient-Reported Outcomes for Adverse Events; Early Career Investigators; Next Steps in Studying the Human Microbiome in Epidemiologic Studies; Next Generation Sequencing (NGS) Coverage Determination; T-Cells as a Drug for the Personalized Immunotherapy of Cancer; and Inter- and Intra-Tumoral Heterogeneity in Pediatric Sarcomas. NCAB members provided insights regarding reports from the NCAB Ad Hoc Subcommittee reports on Global Cancer Research; Population Sciences, Epidemiology, and Disparities; and the BSA Ad Hoc Subcommittee on Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) Malignancy. The Board deliberated on and approved a final report from the Ad Hoc Global Health Working Group and an interim report from the Ad Hoc Data Science Working Group. At the Joint Meeting of the National Advisory Council on Alcohol Abuse and Alcoholism, National Advisory Council on Drug Abuse and NCAB met to hear reports regarding the Adolescent Brain and Cognitive Development (ABCD) Study; a presentation from the U.S. Surgeon General regarding Better Health Through Better Partnerships; and updates from the NIAAA, NIDA, and NCI regarding efforts associated with the Collaborative Research on Addiction at NIH (CRAN) initiative. Lastly, NCAB meeting minutes for the September 2017 meeting, November 2017 Joint NCI Board of Scientific Advisors/NCAB meeting, the NIAAA/NIDA/NCAB May 2018 meeting, the

February 2018 meeting and the June 2018 Joint NCI Board of Scientific Advisors/NCAB meeting were approved by the Board members during fiscal year 2018.

**20b. How does the Committee balance its membership?**

The NCAB consists of 18 members appointed by the President. Not more than twelve of the appointed members are selected from among leading representatives of the health and scientific disciplines (including one in public health and one in the behavioral or social sciences) that are relevant to the activities of the NCI. Not more than six of the appointed members are representatives from the general public, including leaders in fields of public policy, law, health policy, economics and management. Not less than five of the appointed members are individuals knowledgeable in environmental carcinogenesis (including carcinogenesis involving occupational and dietary factors).

**20c. How frequent and relevant are the Committee Meetings?**

Meetings are held not less than four times a year. The committee met five times during this reporting period. The Board met jointly with NIAAA/NIDA on May 16, 2018 and jointly with the NCI Board of Scientific Advisors for the November 2017 and June 2018 meeting. The Board also met virtually at the February 2018 and August 2018 meetings. The NCAB provides advice on a continuing basis on the type of scientific research programs that should be supported and on how best to carry out the designated mission and responsibilities of the NCI. In addition, this Board provides ongoing review of the relevance and effectiveness of the existing scientific programs. The Ad hoc Subcommittee on Global Cancer Research and Ad Hoc Subcommittee on Population Science, Epidemiology and Disparities met on November 28, 2017. The Ad Hoc Subcommittee on Population Science, Epidemiology and Disparities and Ad hoc Subcommittee on Global Cancer Research met on June 25, 2018. The Ad Hoc Working Group on Global Health met April 30, 2018. The Ad Hoc Working Group on Data Science met on May 22, July 25, and September 18, 2018. The Ad Hoc Working Group on SBIR/STTR met on May 29, July 24 and September 20-21, 2018. The Ad Hoc Working Group on Strategic Approaches and Opportunities in Population Science, Epidemiology, and Disparities met on July 19, August 22, September 6, and September 20, 2018.

**20d. Why can't the advice or information this committee provides be obtained elsewhere?**

The NCAB provides second level of peer review and advises on policy development; program implementation, and evaluation; and identifies research needs and opportunities of the Institute. The quality, scope, and balance of advice from this Board cannot be obtained from NIH staff or from other established sources as membership of the Board is constituted to meet specific requirements of the mandated mission of the Board and of the

NCI.

## **20e. Why is it necessary to close and/or partially closed committee meetings?**

The meetings of the NCAB were closed to the public for the review of grant applications. Sections 552b(c)(4) and 552b(c)(6) of the Government in the Sunshine Act permit the closing of meetings where discussion of applications could reveal confidential trade secrets or commercial property such as patentable material and personal information, disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

## **21. Remarks**

Committee Function: Other - National Scientific and Advisory. Costs: The increase in operating costs for FY18 is due to an increase in the number of NCAB working groups and the number of meetings held. Ex Officio Members: The terms of service for Michael Babich, Vincent Cogliano, Aubrey Miller, Richard Pazdur, and Craig Shriver have been extended. As such, their term of service dates are different than what was reported on the FY17 ACR. Members: The terms of service for David Christiani, Judy Garber, Elizabeth Jaffee, Beth Karlan, Mack Roach, and Charles Sawyers have changed due to administrative extensions. As such, their term of service dates are different than what was reported on the FY17 ACR. The DFO and Committee Decision Maker positions are held by the same individual because of the assignment of responsibilities within the Institute.

## **Designated Federal Officer**

PAULETTE S. GRAY DIRECTOR, DIVISION OF EXTRAMURAL ACTIVITIES, NCI

<b>Committee Members</b>	<b>Start</b>	<b>End</b>	<b>Occupation</b>	<b>Member Designation</b>
ADAMSON, PETER	06/18/2015	03/09/2020	CHAIR, CHILDREN'S ONCOLOGY GROUP	Special Government Employee (SGE) Member
ALI-OSMAN, FRANCIS	11/27/2016	03/09/2022	MARGARET HARRIS & DAVID SILVERMAN DISTINGUISHED PROFESSOR OF NEURO-ONCOLOGY RESEARCH	Special Government Employee (SGE) Member
ANDERSON, ROBERT	04/17/2013	12/31/2020	DIRECTOR, BIOLOGICAL SYSTEMS SCIENCE DIVISION	Ex Officio Member
BABICH, MICHAEL	12/04/2000	12/31/2020	DIRECTORATE FOR EPIDEMIOLOGY AND HEALTH SCIENCES	Ex Officio Member
BRUNER, DEBORAH	06/18/2015	03/09/2020	ROBERT W. WOODRUFF CHAIR IN NURSING	Special Government Employee (SGE) Member
CHANG, YUAN	06/18/2015	03/09/2020	AMERICAN CANCER SOCIETY RESEARCH PROFESSOR	Special Government Employee (SGE) Member
CHRISTIANI, DAVID	01/27/2013	09/30/2018	ELKAN BLOUT PROFESSOR OF ENVIRONMENTAL GENETICS	Special Government Employee (SGE) Member
COGLIANO, VINCENT	06/06/2012	12/31/2023	ACTING DIRECTOR, INTEGRATED RISK INFORMATION SYSTEM PROGRAM	Ex Officio Member

GARBER, JUDY	01/27/2013	09/30/2018	DIRECTOR, CENTER FOR CANCER GENETICS AND PREVENTION	Special Government Employee (SGE) Member
GOSTIN, LAWRENCE	11/27/2016	03/09/2022	UNIVERSITY PROFESSOR, FACULTY DIRECTOR, AND FOUNDING LINDA D. AND TIMOTHY J. O'NEILL PROFESSOR IN GLOBAL HEALTH LAW	Special Government Employee (SGE) Member
HIEBERT, SCOTT	11/27/2016	03/09/2022	HORTENSE B. INGRAM CHAIR IN CANCER RESEARCH	Special Government Employee (SGE) Member
JAFFEE, ELIZABETH	01/27/2013	09/30/2018	DEPUTY DIRECTOR, THE SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER	Special Government Employee (SGE) Member
KARLAN, BETH	01/27/2013	09/30/2018	DIRECTOR, WOMEN'S CANCER PROGRAM, SAMUEL OSCHIN COMPREHENSIVE CANCER INSTITUTE	Special Government Employee (SGE) Member
KELLEY, MICHAEL	02/04/2008	12/31/2020	NATIONAL PROGRAM DIRECTOR FOR ONCOLOGY	Ex Officio Member
LEY, TIMOTHY	06/18/2015	03/09/2020	PROFESSOR OF MEDICINE AND GENETICS	Special Government Employee (SGE) Member
MILLER, AUBREY	06/09/2011	12/31/2023	SENIOR MEDICAL ADVISOR	Ex Officio Member
PASKETT, ELECTRA	11/27/2016	03/09/2022	MARION N. ROWLEY PROFESSOR OF CANCER RESEARCH AND DIRECTOR	Special Government Employee (SGE) Member
PAZDUR, RICHARD	09/01/2002	12/31/2020	DIRECTOR, ONCOLOGY CENTER OF EXCELLENCE	Ex Officio Member
RAAB-TRAUB, NANCY	11/27/2016	03/09/2022	PROFESSOR, LINEBERGER COMPREHENSIVE CANCER CENTER	Special Government Employee (SGE) Member
ROACH, MACK	01/27/2013	09/30/2018	PROFESSOR OF RADIATION ONCOLOGY AND UROLOGY AND DIRECTOR	Special Government Employee (SGE) Member
SAWYERS, CHARLES	01/27/2013	09/30/2018	CHAIRMAN, HUMAN ONCOLOGY AND PATHOGENESIS PROGRAM	Special Government Employee (SGE) Member
SHRIVER, CRAIG	08/22/2012	12/31/2023	DIRECTOR, JOHN P. MURTHA CANCER CENTER	Ex Officio Member
SOUZA, KERRY	04/30/2013	12/30/2020	EPIDEMIOLOGIST	Ex Officio Member
SPITZ, MARGARET	11/27/2016	03/09/2022	PROFESSOR, DAN L. DUNCAN CANCER CENTER	Special Government Employee (SGE) Member
THOMAS, RICHARD	08/01/2014	12/31/2019	DEPUTY DIRECTOR, OFFICE OF OCCUPATIONAL MEDICINE	Ex Officio Member
WICHA, MAX	06/18/2015	03/09/2020	DEPUTY DIRECTOR OF THE TAUBMAN INSTITUTE, DISTINGUISHED PROFESSOR OF ONCOLOGY	Special Government Employee (SGE) Member

**Number of Committee Members Listed: 26**

### **Narrative Description**

The goal of NIH research is to acquire new knowledge to help prevent, detect, diagnose, and treat disease and disability, from the rarest genetic disorder to the common cold. The

National Cancer Institute coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients. NCI works to fulfill that mission with the support of the National Cancer Advisory Board (NCAB), which is composed of both scientific and public members, and provides second level peer review, makes recommendations for support of grants, contract proposals, and cooperative agreements, where direct costs per annum exceed \$50,000; advises on policy development, program implementation and evaluation; and identifies research needs of the National Cancer Institute (NCI). During the year, the NCAB was presented reports on various topics related to cancer research in general, and the operational aspects of the Institute's intramural and extramural programs. The NCAB provides advice on a continuing basis on the type of scientific research programs that should be supported and on how best to carry out the designated mission and responsibilities of the NCI. In addition, this Board provides ongoing review of the relevance and effectiveness of the existing research programs.

**What are the most significant program outcomes associated with this committee?**

Checked if Applies

Improvements to health or safety	<input checked="" type="checkbox"/>
Trust in government	<input type="checkbox"/>
Major policy changes	<input checked="" type="checkbox"/>
Advance in scientific research	<input checked="" type="checkbox"/>
Effective grant making	<input checked="" type="checkbox"/>
Improved service delivery	<input type="checkbox"/>
Increased customer satisfaction	<input type="checkbox"/>
Implementation of laws or regulatory requirements	<input checked="" type="checkbox"/>
Other	<input checked="" type="checkbox"/>

**Outcome Comments**

The NCAB continues to be instrumental in monitoring the development and execution of the activities of the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients. In 2018, NCI used its resources to support the best science and ensure continued advances with a focus on the Cancer Moonshot recommendations and associated implementation plans. There were also discussions on early stage investigators and NCI's proposed implementation plan for the NIH Next-Generation Researchers Initiative which included establishing the NCI

Early Cancer Investigator (ECI), awarding successful ECI applications for 5 plus 2 years, providing mentoring for ECIs, and continuing to expend efforts to increase diversity of the NCI-funded workforce. The Board provided insights on NCI's key focus areas – reaffirming commitment to basic science to drive novel approaches and technologies; increasing data aggregation and interpretation to speed work across the cancer enterprise; supporting the cancer research enterprise by focusing on the workforce of cancer investigators; and realizing the power of clinical trials through innovative design, administration, and analyses. NCAB members gave thoughtful advice on several scientific advances presented regarding cervical cancer screening, the human microbiome in epidemiologic studies, the use of T-Cells as a drug for personalized immunotherapy of cancer, and inter- and intra-tumoral heterogeneity in pediatric sarcomas. Additionally, there were discussions regarding the Interim Ad Hoc Data Science Working Group Report and the Final Ad Hoc Global Health Working Group Report which were presented, deliberated, and approved at the August 2018 NCAB Meeting.

**What are the cost savings associated with this committee?**

Checked if Applies

None	<input type="checkbox"/>
Unable to Determine	<input checked="" type="checkbox"/>
Under \$100,000	<input type="checkbox"/>
\$100,000 - \$500,000	<input type="checkbox"/>
\$500,001 - \$1,000,000	<input type="checkbox"/>
\$1,000,001 - \$5,000,000	<input type="checkbox"/>
\$5,000,001 - \$10,000,000	<input type="checkbox"/>
Over \$10,000,000	<input type="checkbox"/>
Cost Savings Other	<input type="checkbox"/>

**Cost Savings Comments**

NIH supported basic and clinical research accomplishments often take many years to unfold into new diagnostic tests and new ways to treat and prevent diseases.

**What is the approximate Number of recommendations produced by this committee for the life of the committee?**

183

**Number of Recommendations Comments**

Comments: FY 2018 recommendations include the following: 1. A motion to confirm the 14–15 August 2018 and 3–5 September 2019 meeting dates of the NCAB was approved unanimously. 2. A motion to accept the minutes of the 12 September 2017 NCAB meeting

was approved unanimously. 3. A motion to accept the report of the 28 November 2017 NCAB Ad Hoc Global Cancer Research Subcommittee meeting was approved unanimously. 4. A motion to accept the report of the 28 November 2017 NCAB Ad Hoc Population Sciences, Epidemiology, and Disparities Subcommittee meeting was approved unanimously. 5. Motions (4 total) to establish NCAB Ad Hoc Working Groups on Global Health; Informatics; Strategic Approaches and Opportunities in Population Science, Epidemiology, and Disparities; and Small Business Innovation Research (SBIR)/Small Business Technology Transfer Research (STTR) were approved unanimously. 6. A motion to accept the minutes of the 29 November 2017 Joint Boards meeting was approved unanimously. 7. A motion to approve the NCI Annual Delegations of Authority was approved unanimously. 8. A motion to accept the minutes of the February 13, 2018 NCAB meeting was approved unanimously. 9. A motion to accept the report of the June 25, 2018 NCAB Ad Hoc Global Cancer Research Subcommittee meeting was approved unanimously. 10. A motion to accept the report of the June 25, 2018 NCAB Ad Hoc Population Science, Epidemiology, and Disparities Subcommittee meeting was approved unanimously. 11. A motion to accept the minutes of the June 26–27, 2018 NCAB and Board of Scientific Advisors Joint Meeting was approved unanimously. 12. A motion to accept the interim report of the NCAB ad hoc Data Science Working Group was approved unanimously. 13. A motion to accept the final report of the NCAB ad hoc Global Health Working Group was approved unanimously.

**What is the approximate Percentage of these recommendations that have been or will be Fully implemented by the agency?**

0%

**% of Recommendations Fully Implemented Comments**

Information on the research funded by NIH is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at <http://report.nih.gov>.

**What is the approximate Percentage of these recommendations that have been or will be Partially implemented by the agency?**

0%

**% of Recommendations Partially Implemented Comments**

Information on the research funded by NIH is available through the RePORT (Research



Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at <http://report.nih.gov>.

**Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered?**

Yes ☒ No ☐ Not Applicable ☐

**Agency Feedback Comments**

NCI Director and Deputy Directors report at each Board Meeting; the President's Cancer Panel Report; NCI Annual Reports; Biennial reports; and a list of Action Items for each meeting are reviewed and assigned to individual NCI staff with specific time frames with deadlines.

**What other actions has the agency taken as a result of the committee's advice or recommendation?**

	Checked if Applies
Reorganized Priorities	<input checked="" type="checkbox"/>
Reallocated resources	<input checked="" type="checkbox"/>
Issued new regulation	<input type="checkbox"/>
Proposed legislation	<input type="checkbox"/>
Approved grants or other payments	<input checked="" type="checkbox"/>
Other	<input checked="" type="checkbox"/>

**Action Comments**

An action of approved or recommended for grants receiving review by this Council does not infer that the grant will be or has been funded. Research grant applications submitted to NIH must go through a two-step review process that includes the initial peer review for scientific and technical merit and a second step of review and approval by the National Advisory Council that includes program relevance. In addition, prior to an award or funding being made, NIH staff must conduct an administrative review for a number of other considerations. These include alignment with NIH's funding principles, review of the project budget, assessment of the applicant's management systems, determination of applicant eligibility, and compliance with public policy requirements. After all these steps, have been completed, NIH officials make funding decisions on individual grant applications. NCI used its resources to support the best science and ensure continued advances with a focus on the Cancer Moonshot recommendations and associated

implementation plans. There were also discussions on early stage investigators and NCI's proposed implementation plan for the NIH Next-General Researchers Initiative which included establishing the NCI Early Cancer Investigator (ECI), awarding successful ECI applications for 5 plus 2 years, providing mentoring for ECIs, and continuing to expend efforts to increase diversity of the NCI-funded workforce. The Board provided insights on NCI's key focus areas – reaffirming commitment to basic science to drive novel approaches and technologies; increasing data aggregation and interpretation to speed work across the cancer enterprise; supporting the cancer research enterprise by focusing on the workforce of cancer investigators; and realizing the power of clinical trials through innovative design, administration, and analyses. NCAB members gave thoughtful advice on several scientific advances presented regarding cervical cancer screening, the human microbiome in epidemiologic studies, the use of T-Cells as a drug for personalized immunotherapy of cancer, and inter- and intra-tumoral heterogeneity in pediatric sarcomas. Additionally, there were discussions regarding the Interim Ad Hoc Data Science Working Group Report and the Final Ad Hoc Global Health Working Group Report which were presented, deliberated, and approved at the August 2018 NCAB Meeting.

#### **Is the Committee engaged in the review of applications for grants?**

Yes

What is the estimated <b><u>Number</u></b> of grants reviewed for approval	15,127
What is the estimated <b><u>Number</u></b> of grants recommended for approval	15,127
What is the estimated <b><u>Dollar Value</u></b> of grants recommended for approval	\$848,848,667

#### **Grant Review Comments**

The number of grants reviewed/recommended and dollar value includes NCI grants and FDA SBIR grants.

#### **How is access provided to the information for the Committee's documentation?**

Checked if Applies

Contact DFO	<input checked="" type="checkbox"/>
Online Agency Web Site	<input checked="" type="checkbox"/>
Online Committee Web Site	<input checked="" type="checkbox"/>
Online GSA FACA Web Site	<input checked="" type="checkbox"/>
Publications	<input checked="" type="checkbox"/>
Other	<input checked="" type="checkbox"/>

#### **Access Comments**

Information on the NCAB can be found at the NCI Division of Extramural Activities:

Advisory Boards, Committees and Review Groups website at <https://deainfo.nci.nih.gov/advisory/ncab/ncab.htm>. Each NCI committee's charter, minutes, agenda, roster, future meeting dates, meeting PowerPoint Presentations and reports is located here. Additionally, the public may view the NCAB meetings (both live and on demand) via the NIH Videocast at the following website: <http://videocast.nih.gov/>.